Real-time monitoring of 2,5-dimethylpyrazine in solid, liquid, and gas phases during processing of fried skipjack tuna steaks using intestinal villus-like Ag nanoparticles@Au nanowires surface-enhanced Raman substrate chips

Article

Author: Jiang, Jing ; Liu, Min ; Xu, Dalun ; Xiang, Leiwen ; Jiang, Tao ; Zhang, Jinjie ; Wu, Huawei

The production and distribution of 2,5-dimethylpyrazine (2,5-DMP), a key volatile flavor compound, are associated with the frying of skipjack tuna steaks. In this study, an intestinal villus-like chip was fabricated to quantitatively detect 2,5-DMP in multiphase systems based on surface-enhanced Raman spectroscopy (SERS). The chip exhibited excellent SERS performance with an enhancement factor of 1.16 × 10⁸, excellent uniformity and reproducibility, and low detection limits of 6.49 pg/mL, 0.182, and 0.920 ng/mL for 2,5-DMP solid, liquid, and gas models, respectively. The results indicated the 2,5-DMP content with growth rates in the order of frying steam > frying steaks > frying oil, and the 2,5-DMP content in frying steam was linearly correlated (R² = 0.992) with the trend of the acid value and total polar compounds in frying oil. Therefore, this strategy for achieving the reliable detection of 2,5-DMP can assist in monitoring the frying process and food safety.

01 Oct 2023·International archives of occupational and environmental health

Association of volatile organic compounds exposure with the risk of depression in U.S. adults: a cross‑sectional study from NHANES 2013-2016.

Article

Author: Wang, Menglin ; Zhu, Yue ; Ju, Yinghui ; Yang, Yuying ; Wu, Rui

BACKGROUNDVolatile organic compounds (VOCs) are a broad class of chemicals, and previous studies showed that VOCs could increase the risk of central nervous system disorders. However, few studies have comprehensively explored their association with depression among general adults.OBJECTIVEWe aimed to explore the association between blood VOCs and depression risk based on a large cross-sectional study of the National Health and Nutrition Examination Survey (NHANES).METHODSWe analyzed data from 3449 American adults in the NHANES 2013-2016. Survey-weighted logistic regression model was used to explore the association of ten blood VOCs with depression. Subsequently, the relative importance of the selected VOCs was determined using the XGBoost model. The weighted quantile sum (WQS) regression model was used to explore the overall association of 10 blood VOCs with depression. Subgroup analyses were performed to identify high-risk populations. Finally, restricted cubic spline (RCS) analysis was utilized to explore the dose-response relationship between blood VOCs and the risk of depression.RESULTSXGBoost Algorithm model identified blood 2,5-dimethylfuran was the most critical variable in depression. The logistic regression model showed that blood benzene, blood 2,5-dimethylfuran, and blood furan showed a positive correlation with depression. In subgroup analysis, we found that the effects of the above VOCs on depression existed among the female, young middle-aged, and overweight-obese population. Mixture VOCs exposure was positively associated with depression risk (OR = 2.089, 95% CI: 1.299-3.361), and 2,5-dimethylfuran had the largest weights in WQS regression. RCS displayed that blood benzene, blood 2,5-dimethylfuran, and blood furan were positively associated with depression.CONCLUSIONThe results of this study indicated that VOCs exposure was associated with an increased prevalence of depression in U.S. adults. Women, young and middle-aged, and overweight-obese populations are more vulnerable to VOCs.

01 May 2019·The American Journal of Geriatric PsychiatryQ2 · MEDICINE

Two Interventions for PatientsWith Major Depression and Severe Chronic Obstructive Pulmonary Disease: Impact on Quality of Life

Q2 · MEDICINE

Article

Author: Pollari, Cristina ; Sirey, Jo Anne ; Jackson, Danielle S ; Banerjee, Samprit ; Wu, Yiyuan ; Chalfin, Alexandra ; Solomonov, Nili ; Alexopoulos, George S ; Novitch, Richard

OBJECTIVEClinically significant depression occurs in approximately 40% of chronic obstructive pulmonary disease (COPD) patients, and both illnesses severely impair quality of life. This study tests the hypothesis that problem-solving integrated with a treatment adherence intervention, the Problem Solving-Adherence (PSA), is superior to a personalized treatment adherence intervention, the Personalized Intervention for Depressed Patients with COPD (PID-C), alone in improving quality of life in depressed COPD patients.METHODSAfter screening 633 admissions for acute rehabilitation, we studied quality of life in 87 participants with major depression (by Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition) and severe COPD randomly assigned to 14 sessions of PID-C or PSA over 26 weeks. Quality of life was assessed using the Word Health Organization Quality of Life-BREF at baseline and weeks 10, 14, and 26.RESULTSThe hypothesis was not supported. Exploratory latent class growth modeling identified two quality of life trajectories. In 80.5% of participants, quality of life remained unchanged and improved in the remaining 19.5% during the first 14 weeks. Patients with a stable quality trajectory had higher qualityof life at baseline and a stronger sense of personal agency.CONCLUSIONMaintaining quality of life is a favorable outcome in depressed patients with COPD whose course is one of deterioration. These findings highlight the usefulness of PID-C, an easy to learn, personalized adherence enhancement intervention that, after further testing, may be integrated into the rehabilitation and care of depressed COPD patients.

100 Deals associated with DM-C

R&D Status

10 top R&D records.

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Inflammation	Preclinical	JP	University Of occupation & Environmental Health Japan	01 Feb 2024
Myocardial Infarction	Preclinical	JP	University Of occupation & Environmental Health Japan	01 Feb 2024

Clinical Result

Indication

Phase

Evaluation

View All Results

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Deal

Boost your decision using our deal data.

view full example data

Core Patent

Boost your research with our Core Patent data.

view full example data

Clinical Trial

Identify the latest clinical trials across global registries.

view full example data

Approval

Accelerate your research with the latest regulatory approval information.

view full example data

Regulation

Understand key drug designations in just a few clicks with Synapse.

view full example data

Chat with Hiro

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis


No Data

DM-C

Overview

Basic Info

Related

R&D Status

Clinical Result

Translational Medicine

Deal

Core Patent

Clinical Trial

Approval

Regulation